Migraines affect one in seven Americans, and are twice as prevalent in women versus men. If you’re not familiar with the affliction, it’s essentially a severe headache accompanied by nausea and sensitivity to light and sound. Thankfully, a recent CNBC article noted the FDA’s approval of a new drug from Eli Lilly that treats them quickly. Reyvow is the first drug to score approval in the first new drug class for migraines in two decades.
The FDA’s green light comes after two studies showed that patients who took the drug were more likely to have their migraine symptoms resolved after two hours than those who took placebos. Side effects reported by participants in the study include dizziness, fatigue, sedation, and paresthesia (a burning sensation in the skin), all of which I’d gladly take over a prolonged migraine.
